Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Comparison of the Different Medications for COVID-19 in Kidney Transplant Recipients

Fu et al., Authorea, Inc., doi:10.22541/au.168777909.90198442/v1
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ventilation -280% Improvement Relative Risk ICU admission -659% AKI -207% Paxlovid for COVID-19  Fu et al.  LATE TREATMENT Is late treatment with paxlovid beneficial for COVID-19? Retrospective 111 patients in China (December 2022 - January 2023) Study compares with azvudine, results vs. placebo may differ Higher progression with paxlovid (p=0.0047) c19early.org Fu et al., Authorea, Inc., June 2023 Favorspaxlovid Favorsazvudine 0 0.5 1 1.5 2+
Retrospective 140 kidney transplant patients, showing higher risk of AKI with paxlovid compared with azvudine. There were more severe cases in the paxlovid group at baseline.
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid1. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid"2.
Resistant variants are likely3,4.
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of mechanical ventilation, 279.6% higher, RR 3.80, p = 0.32, treatment 3 of 49 (6.1%), control 1 of 62 (1.6%).
risk of ICU admission, 659.2% higher, RR 7.59, p = 0.04, treatment 6 of 49 (12.2%), control 1 of 62 (1.6%).
AKI, 207.3% higher, RR 3.07, p = 0.005, treatment 17 of 49 (34.7%), control 7 of 62 (11.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fu et al., 26 Jun 2023, retrospective, China, preprint, mean age 47.3, 8 authors, study period December 2022 - January 2023, this trial compares with another treatment - results may be better when compared to placebo.
This PaperPaxlovidAll
Comparison of the Different Medications for COVID-19 in Kidney Transplant Recipients
Yingxin Fu, Jianyong Pan, Weijun Chen, Yitao Zheng, Zixuan Wu, Yongdong Liu, Yuanzheng Peng, Hongzhou Lu
doi:10.22541/au.168777909.90198442/v1
Background We analyzed the effects of small-molecule antiviral treatment for coronavirus disease-2019 (COVID-19) Omicron strain in kidney transplant recipients. Methods We enrolled 140 kidney transplant patients admitted for COVID-19-related pneumonia were treated using small-molecule antivirals. Patients were divided into three groups: azvudine (n=62), paxlovid (n=49), and a combination of azvudine+paxlovid (A+P, n=29). Differences in clinical outcomes owing to COVID-19 infections were compared among three groups. Results Paxlovid group had a higher proportion of comorbid diabetes than the other two groups (P=0.032). There were differences in the clinical typing of the coronavirus , with the highest proportion of heavy and critical cases in the A+P group (35.5%). The immunosuppression prior to infection did not differ among the groups; however, after adjusting for immunosuppression during antiviral treatment, differences were observed. Of the 140 patients, 125 (89.29%) had fever, 114 (81.43%) had cough, and 66 (47.1%) had malaise. Combination of two or more symptoms were found in 90% patients. Mean length of hospitalization was slightly longer in the combination group than in the azvudine and paxlovid groups. Four deaths, all in the A+P group; five cases of loss of function, two in the paxlovid group and three in the A+P group; and acute kidney injury occurred in 30 patients with 7 in the azvudine, 17 in paxlovid, and 6 in A+P groups. Conclusion The use of small-molecule medications may be the optimal treatment approach; however, they should be modified based on the patients' conditions, such as clinical symptoms, laboratory results, paraclinicals, and examinations.
CONCLUSION The use of small-molecule medications may be the optimal treatment approach; however, they should be modified based on the patients' conditions, such as clinical symptoms, laboratory results, paraclinicals, and examinations. References
References
Akalin, Azzi, Bartash, Covid-19 and kidney transplantation[J], N Engl J Med
Ao, Wang, Qi, The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis, Transplant Rev (Orlando)
Baig, Khaleeq, Ali, Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms [J], ACS Chemical Neuroscience
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19-final report, N Engl J Med
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of covid-19 in nonhospitalized patients, N Engl J Med
Callaway, Heavily mutated Omicron variant puts scientists on alert [J], Nature
Chaplin, Paxlovid: antiviral combination for the treatment of COVID-19, Prescriber
Chen, Shi, Dong, SARS-CoV-2 Lambda variant: spatiotemporal distribution and potential, Zoonoses
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, J]. Lancet
Farouk, Fiaccadori, Cravedi, COVID-19 and the kidney: what we think we know so far and what we don't [J], J Nephrol
Gottlieb, Vaca, Paredes, Early remdesivir to prevent progression to severe covid-19 in outpatients, N Engl J Med
Hammitt, Dagan, Yuan, Nirsevimab for prevention of RSV in healthy late-preterm and term infants [J], New Engl J Med
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for highrisk, nonhospitalized adults with covid-19, N Engl J Med
Hirose R, Itoh, Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1and BA.2 have higher stability, J]. Clin Microbiol Infect
Hui, Zumla, Severe acute respiratory syndrome historical, epidemiologic, and clinical features, Infect Dis Clin N Am
Loo, Mctamney, Arends R H, The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans [J], Science translational medicine
Piechotta, Iannizzi, Chai, Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database Syst Rev
Plante, Liu, Liu, Author Correction: Spike mutation D614G alters SARS-CoV-2 fitness [J], Nature
Pulliam, Van Schalkwyk, Govender, Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa, Science
Van Doremalen N, Bushmaker, Dh, Aerosol and surface stability of SARS-Cov-2 as compared with SARS-CoV-1 [J], N Engl J Med
Yokota, Miyamae, Imagawa, Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis, Arthritis & Rheumatism
Zhang, Wang, Guo, Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report, Signal Transduction & Targeted Therapy
{ 'institution': [{'name': 'Authorea, Inc.'}], 'indexed': {'date-parts': [[2023, 6, 27]], 'date-time': '2023-06-27T04:35:24Z', 'timestamp': 1687840524403}, 'posted': {'date-parts': [[2023, 6, 26]]}, 'group-title': 'Preprints', 'reference-count': 0, 'publisher': 'Authorea, Inc.', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2023, 6, 26]]}, 'abstract': '<jats:p id="p1">Background We analyzed the effects of small-molecule antiviral treatment\n' 'for coronavirus disease-2019 (COVID-19) Omicron strain in kidney\n' 'transplant recipients. Methods We enrolled 140 kidney transplant\n' 'patients admitted for COVID-19-related pneumonia were treated using\n' 'small-molecule antivirals. Patients were divided into three groups:\n' 'azvudine (n=62), paxlovid (n=49), and a combination of azvudine+paxlovid\n' '(A+P, n=29). Differences in clinical outcomes owing to COVID-19\n' 'infections were compared among three groups. Results Paxlovid group had\n' 'a higher proportion of comorbid diabetes than the other two groups\n' '(P=0.032). There were differences in the clinical typing of the\n' 'coronavirus , with the highest proportion of heavy and critical cases in\n' 'the A+P group (35.5%). The immunosuppression prior to infection did not\n' 'differ among the groups; however, after adjusting for immunosuppression\n' 'during antiviral treatment, differences were observed. Of the 140\n' 'patients, 125 (89.29%) had fever, 114 (81.43%) had cough, and 66\n' '(47.1%) had malaise. Combination of two or more symptoms were found in\n' '90% patients. Mean length of hospitalization was slightly longer in the\n' 'combination group than in the azvudine and paxlovid groups. Four deaths,\n' 'all in the A+P group; five cases of loss of function, two in the\n' 'paxlovid group and three in the A+P group; and acute kidney injury\n' 'occurred in 30 patients with 7 in the azvudine, 17 in paxlovid, and 6 in\n' 'A+P groups. Conclusion The use of small-molecule medications may be the\n' 'optimal treatment approach; however, they should be modified based on\n' 'the patients’ conditions, such as clinical symptoms, laboratory results,\n' 'paraclinicals, and examinations.</jats:p>', 'DOI': '10.22541/au.168777909.90198442/v1', 'type': 'posted-content', 'created': {'date-parts': [[2023, 6, 26]], 'date-time': '2023-06-26T11:31:39Z', 'timestamp': 1687779099000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Comparison of the Different Medications for COVID-19 in Kidney Transplant Recipients', 'prefix': '10.22541', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2247-8684', 'authenticated-orcid': True, 'given': 'Yingxin', 'family': 'Fu', 'sequence': 'first', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}, { 'given': 'Jianyong', 'family': 'Pan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}, { 'given': 'Weijun', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}, { 'given': 'Yitao', 'family': 'Zheng', 'sequence': 'additional', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}, { 'given': 'Zixuan', 'family': 'Wu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}, { 'given': 'Yongdong', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}, { 'given': 'Yuanzheng', 'family': 'Peng', 'sequence': 'additional', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}, { 'given': 'Hongzhou', 'family': 'Lu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Second Affiliated Hospital of Southern University of Science and ' 'Technology'}]}], 'member': '9829', 'container-title': [], 'original-title': [], 'deposited': { 'date-parts': [[2023, 6, 26]], 'date-time': '2023-06-26T11:31:39Z', 'timestamp': 1687779099000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.authorea.com/users/632878/articles/651497-comparison-of-the-different-medications-for-covid-19-in-kidney-transplant-recipients?commit=ab4741e389c91904de90a9ce527e183d368e45d0'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 6, 26]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.22541/au.168777909.90198442/v1', 'relation': {}, 'published': {'date-parts': [[2023, 6, 26]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit